PubMed ID:
22198704
Public Release Type:
Journal
Publication Year: 2012
Affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8887, USA.
DOI:
https://doi.org/10.1007/s10620-011-2013-3
Authors:
Chung RT,
Lee WM,
Lee WM,
Acute Liver Failure Study Group,
Ajmera V,
Blei A,
Brown R,
Crippin J,
Dao DY,
Davern T,
Fontana R,
Han SH,
Harrison E,
Hassanein T,
Hay J,
Hynan L,
Hynan LS,
Lalani E,
Larson AM,
McCashland T,
McGuire B,
Munoz S,
Murray M,
Murray N,
Ostapowicz GA,
Pezzia C,
Polson J,
Reddy R,
Reisch J,
Reuben A,
Rossaro L,
Samuel G,
Sanders C,
Sanders C,
Satyanarayana R,
Schilsky M,
Schiødt FV,
Seremba E,
Shaikh A,
Smith A,
Smith JP,
Stravitz R,
Webster JW,
Zaman A
Studies:
Acute Liver Failure Study Group: Adult Acute Liver Failure Study
The efficacy of nucleoside(tide) analogues (NA) in the treatment of acute liver failure due to hepatitis B virus (HBV-ALF) remains controversial. We determined retrospectively the impact of NAs in a large cohort of patients with HBV-ALF.